Holen Sie sich die Stockscreener-App
291.04
0.65%
1.89
Handel nachbörslich:
280.35
-10.69
-3.67%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$289.15
Offen:
$291.29
24-Stunden-Volumen:
1.27M
Relative Volume:
0.94
Marktkapitalisierung:
$56.43B
Einnahmen:
$316.65B
Nettoeinkommen (Verlust:
$1.90B
KGV:
29.94
EPS:
9.72
Netto-Cashflow:
$1.14B
1W Leistung:
+2.56%
1M Leistung:
-1.41%
6M Leistung:
+19.02%
1J Leistung:
+23.16%
1-Tages-Spanne:
$289.09
$293.56
1-Wochen-Bereich:
$275.14
$293.56
52-Wochen-Spanne:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
291.04 | 56.06B | 316.65B | 1.90B | 1.14B | 9.72 |
|
MCK
Mckesson Corporation
|
663.17 | 81.97B | 377.60B | 3.16B | 5.67B | 25.08 |
|
CAH
Cardinal Health Inc
|
148.12 | 34.92B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
68.99 | 8.19B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.77 | 689.96M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Cencora (COR) Stock Surpasses Market Gains with Strong PerformanceNews and Statistics - IndexBox
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
Cencora Stock: Analyst Estimates & Ratings - inkl
Wells Fargo raises Cencora stock price target to $354 on strong U.S. Healthcare performance - Investing.com Nigeria
Cencora price target raised to $354 from $337 at Wells Fargo - TipRanks
Will Cencora Inc. stock go up in YEARProduct Launch & Real-Time Sentiment Analysis - newsyoung.net
Stock Analysis | Cencora OutlookMixed Signals as Technicals and Analysts Diverge - AInvest
Investors Still Waiting For A Pull Back In Cencora, Inc. (NYSE:COR) - 富途牛牛
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap (NYSE:COR) - Seeking Alpha
Cencora Lifts Earnings Outlook After Strong Q3 Performance - MSN
Cencora & The Lash Group Settle Data Breach Litigation for $40 Million - The HIPAA Journal
Cencora (COR) Shares Jump 1.95% as Trading Volume Surges to $530M Ranking 184th in Market Activity - AInvest
3 Reasons Growth Investors Will Love Cencora (COR) - Yahoo Finance
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - simplywall.st
Why You Might Be Interested In Cencora, Inc. (NYSE:COR) For Its Upcoming Dividend - ca.finance.yahoo.com
Published on: 2025-08-10 00:34:30 - metal.it
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Cencora Rises 2.42% as Trading Volume Slumps to 313th Market Rank - AInvest
Cencora Q3: Growing Specialty Drug Distributions; Initiate At Buy (NYSE:COR) - Seeking Alpha
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results? - MSN
Cencora, Inc. Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora: Fiscal Q3 Earnings Snapshot - New Haven Register
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend - simplywall.st
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Cencora Earnings: Solid Results Illustrate Healthy Demand and Stable Outlook; Shares Fairly Valued - Morningstar
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook - AOL.com
Cencora Benefits From Strong GLP-1 Sales, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora, Inc. SEC 10-Q Report - TradingView
Cencora raises 2025 EPS guidance to $15.85–$16 and narrows outlook as specialty drives growth - MSN
Cencora weakness after earnings ‘overdone,’ says Leerink - TipRanks
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised - The Globe and Mail
Earnings call transcript: Cencora Inc. beats Q3 2025 expectations, stock dips - Investing.com Nigeria
Transcript : Cencora, Inc., Q3 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Cencora (COR) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Cencora Q3 2025 slides: U.S. segment drives 19.8% EPS growth, guidance raised By Investing.com - Investing.com South Africa
Cencora Q3 2025 slides: U.S. segment drives 19.8% EPS growth, guidance raised - Investing.com
Cencora, Inc. Exceeds Expectations with Strong Fiscal Q3 EarningsNews and Statistics - IndexBox
Cencora Inc (COR) Q3 2025 Earnings: EPS of $3.52 Beats Estimates, Revenue Hits $80.7 Billion - GuruFocus
Cencora beats Q3 expectations, raises full-year earnings outlook By Investing.com - Investing.com Australia
Cencora, Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
Cencora beats Q3 expectations, raises full-year earnings outlook - Investing.com
Cencora Inc earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
Cencora’s (NYSE:COR) Q2 Sales Top Estimates - Yahoo Finance
Cencora Earnings Soar Past Estimates as Healthcare Giant Boosts 2025 Profit Outlook - Stock Titan
Cencora's $440M Volume Surge Ranks 281st Amid 0.44% Drop as Liquidity-Driven Gains Outpace Market - AInvest
Mallinckrodt Names Leslie Donato to Board of Directors - BioSpace
Cencora & The Lash Group reach $40M settlement in data breach class action - Claim Depot
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
4.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):